Janina Krell-Roesch1, Jeremy A Syrjanen1, Martin Rakusa1, Prashanthi Vemuri1, Mary M Machulda1, Walter K Kremers1, Michelle M Mielke1, Val J Lowe1, Clifford R Jack1, David S Knopman1, Gorazd B Stokin1, Ronald C Petersen1, Maria Vassilaki1, Yonas E Geda1. 1. Departments of Health Sciences Research (Krell-Roesch, Syrjanen, Rakusa, Kremers, Mielke, Vassilaki), Radiology (Vemuri, Lowe, Jack), Psychiatry and Psychology (Machulda), and Neurology (Mielke, Knopman, Petersen), Mayo Clinic, Rochester, Minn.; Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany (Krell-Roesch); Department of Neurology, University Medical Center, Maribor, Slovenia (Rakusa); International Clinical Research Center, St. Anne Hospital, Brno, Czech Republic (Stokin); and Department of Neurology, Barrow Neurological Institute, Phoenix (Geda).
Abstract
OBJECTIVE: The purpose of this study was to test the hypothesis that subcortical β-amyloid (Aβ) deposition was associated with elevated scores on standardized measures of depressive and anxiety symptoms when compared with cortical (Aβ) deposition in persons without dementia. METHODS: The authors performed a cross-sectional study, derived from the population-based Mayo Clinic Study of Aging, comprising participants aged ≥70 years (N=1,022; 55% males; 28% apolipoprotein E [APOE] ε4 carriers; without cognitive impairment, N=842; mild cognitive impairment; N=180). To assess Aβ deposition in cortical and subcortical (the amygdala, striatum, and thalamus) regions, participants underwent Pittsburgh Compound B positron emission tomography (PiB-PET) and completed the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI). The investigators ran linear regression models to examine the association between PiB-PET standardized uptake value ratios (SUVRs) in the neocortex and subcortical regions and depressive and anxiety symptoms (BDI-II and BAI total scores). Models were adjusted for age, sex, education level, and APOE ε4 carrier status and stratified by cognitive status (without cognitive impairment, mild cognitive impairment). RESULTS: Cortical PiB-PET SUVRs were associated with depressive symptoms (β=0.57 [SE=0.13], p<0.001) and anxiety symptoms (β=0.34 [SE=0.13], p=0.011). PiB-PET SUVRs in the amygdala were associated only with depressive symptoms (β=0.80 [SE=0.26], p=0.002). PiB-PET SUVRs in the striatum and thalamus were associated with depressive symptoms (striatum: β=0.69 [SE=0.18], p<0.001; thalamus: β=0.61 [SE=0.24], p=0.011) and anxiety symptoms (striatum: β=0.56 [SE=0.18], p=0.002; thalamus: β=0.65 [SE=0.24], p=0.008). In the mild cognitive impairment subsample, Aβ deposition, regardless of neuroanatomic location, was associated with depressive symptoms but not anxiety symptoms. CONCLUSIONS: Elevated amyloid deposition in cortical and subcortical brain regions was associated with higher depressive and anxiety symptoms, although these findings did not significantly differ by cortical versus subcortical Aβ deposition. This cross-sectional observation needs to be confirmed by a longitudinal study.
OBJECTIVE: The purpose of this study was to test the hypothesis that subcortical β-amyloid (Aβ) deposition was associated with elevated scores on standardized measures of depressive and anxiety symptoms when compared with cortical (Aβ) deposition in persons without dementia. METHODS: The authors performed a cross-sectional study, derived from the population-based Mayo Clinic Study of Aging, comprising participants aged ≥70 years (N=1,022; 55% males; 28% apolipoprotein E [APOE] ε4 carriers; without cognitive impairment, N=842; mild cognitive impairment; N=180). To assess Aβ deposition in cortical and subcortical (the amygdala, striatum, and thalamus) regions, participants underwent Pittsburgh Compound B positron emission tomography (PiB-PET) and completed the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI). The investigators ran linear regression models to examine the association between PiB-PET standardized uptake value ratios (SUVRs) in the neocortex and subcortical regions and depressive and anxiety symptoms (BDI-II and BAI total scores). Models were adjusted for age, sex, education level, and APOE ε4 carrier status and stratified by cognitive status (without cognitive impairment, mild cognitive impairment). RESULTS: Cortical PiB-PET SUVRs were associated with depressive symptoms (β=0.57 [SE=0.13], p<0.001) and anxiety symptoms (β=0.34 [SE=0.13], p=0.011). PiB-PET SUVRs in the amygdala were associated only with depressive symptoms (β=0.80 [SE=0.26], p=0.002). PiB-PET SUVRs in the striatum and thalamus were associated with depressive symptoms (striatum: β=0.69 [SE=0.18], p<0.001; thalamus: β=0.61 [SE=0.24], p=0.011) and anxiety symptoms (striatum: β=0.56 [SE=0.18], p=0.002; thalamus: β=0.65 [SE=0.24], p=0.008). In the mild cognitive impairment subsample, Aβ deposition, regardless of neuroanatomic location, was associated with depressive symptoms but not anxiety symptoms. CONCLUSIONS: Elevated amyloid deposition in cortical and subcortical brain regions was associated with higher depressive and anxiety symptoms, although these findings did not significantly differ by cortical versus subcortical Aβ deposition. This cross-sectional observation needs to be confirmed by a longitudinal study.
Authors: Constantine G Lyketsos; Oscar Lopez; Beverly Jones; Annette L Fitzpatrick; John Breitner; Steven DeKosky Journal: JAMA Date: 2002-09-25 Impact factor: 56.272
Authors: Val J Lowe; Bradley J Kemp; Clifford R Jack; Matthew Senjem; Stephen Weigand; Maria Shiung; Glenn Smith; David Knopman; Bradley Boeve; Brian Mullan; Ronald C Petersen Journal: J Nucl Med Date: 2009-05-14 Impact factor: 10.057
Authors: Yonas E Geda; Lon S Schneider; Laura N Gitlin; David S Miller; Gwenn S Smith; Joanne Bell; Jovier Evans; Michael Lee; Anton Porsteinsson; Krista L Lanctôt; Paul B Rosenberg; David L Sultzer; Paul T Francis; Henry Brodaty; Prasad P Padala; Chiadikaobi U Onyike; Luis Agüera Ortiz; Sonia Ancoli-Israel; Donald L Bliwise; Jennifer L Martin; Michael V Vitiello; Kristine Yaffe; Phyllis C Zee; Nathan Herrmann; Robert A Sweet; Clive Ballard; Ni A Khin; Cara Alfaro; Patrick S Murray; Susan Schultz; Constantine G Lyketsos Journal: Alzheimers Dement Date: 2013-04-03 Impact factor: 21.566
Authors: Karra D Harrington; Emma Gould; Yen Ying Lim; David Ames; Robert H Pietrzak; Alan Rembach; Stephanie Rainey-Smith; Ralph N Martins; Olivier Salvado; Victor L Villemagne; Christopher C Rowe; Colin L Masters; Paul Maruff Journal: Int J Geriatr Psychiatry Date: 2016-04-25 Impact factor: 3.485
Authors: Janina Krell-Roesch; Val J Lowe; Jennifer Neureiter; Anna Pink; Rosebud O Roberts; Michelle M Mielke; Prashanthi Vemuri; Gorazd B Stokin; Teresa J Christianson; Clifford R Jack; David S Knopman; Bradley F Boeve; Walter K Kremers; Ronald C Petersen; Yonas E Geda Journal: Int Psychogeriatr Date: 2017-12-04 Impact factor: 3.878
Authors: Yonas E Geda; Rosebud O Roberts; Michelle M Mielke; David S Knopman; Teresa J H Christianson; Vernon S Pankratz; Bradley F Boeve; Ondrej Sochor; Eric G Tangalos; Ronald C Petersen; Walter A Rocca Journal: Am J Psychiatry Date: 2014-05 Impact factor: 18.112
Authors: Firoza Z Lussier; Tharick A Pascoal; Mira Chamoun; Joseph Therriault; Cécile Tissot; Mélissa Savard; Min Su Kang; Sulantha Mathotaarachchi; Andrea L Benedet; Marlee Parsons; Muhammad Naveed Iqbal Qureshi; Émilie M Thomas; Monica Shin; Laurie-Anne Dion; Gassan Massarweh; Jean-Paul Soucy; I-Huang Tsai; Paolo Vitali; Zahinoor Ismail; Pedro Rosa-Neto; Serge Gauthier Journal: Alzheimers Dement Date: 2020-01 Impact factor: 21.566
Authors: Jan S Novotný; Juan P Gonzalez-Rivas; Jose R Medina-Inojosa; Francisco Lopez-Jimenez; Yonas E Geda; Gorazd B Stokin Journal: Alzheimers Dement (N Y) Date: 2021-12-31